Metabolomic profiling reveals interindividual metabolic variability and its association with cardiovascular-kidney-metabolic syndrome risk
Authors' conclusion
Untargeted plasma metabolomic profiling reveals distinct metabolic subtypes corresponding to CKM severity and uncovers marked heterogeneity within the high-risk group. Key metabolite signatures may enhance early risk stratification and support more personalized management strategies beyond conventional CKM staging.
Study context
- Population
- Adults, including 86 clinically staged as cardiovascular-Kidney-Metabolic (CKM) 0–3 per American Heart Association (AHA) criteria86 staged CKM 0–3
- Participants
- 163 adults
- Exposure
- Metabolic clusters by CKM risk
- Outcome
- Metabolic clusters and CKM risk
Methodological detailsuntargeted metabolomic and lipidomic profiling (liquid chromatography-mass spectrometry (LC-MS)), unsupervised clustering with random forest validation
- Untargeted metabolomic and lipidomic profiling (LC-MS)
- Unsupervised clustering with random forest validation
Main finding
As reported in the abstract
- Metabolites identified (9 superclasses, 30 subclasses)
- 390
- High-risk CKM individuals predominantly assigned to Cluster 3
- p < 0.001
Observational data: associations, not effects.
Further findings
Secondary clustering among CKM stage 3
- Substantial metabolic heterogeneity
Diagnostic performance of 20-metabolite panel for CKM stage 3
- AUC
- 0.875
Original publication
Metabolomic profiling reveals interindividual metabolic variability and its association with cardiovascular-kidney-metabolic syndrome risk. Cardiovasc Diabetol. Published 1 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →